相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
Paul Nghiem et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis
Xiaoying Sun et al.
BMC CANCER (2019)
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
M. R. Migden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma A Preplanned Interim Analysis of a Clinical Trial
Sandra P. D'Angelo et al.
JAMA ONCOLOGY (2018)
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
N. Basset-Seguin et al.
EUROPEAN JOURNAL OF CANCER (2017)
Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma
Paul Nghiem et al.
FUTURE ONCOLOGY (2017)
Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study
Aleksandar Sekulic et al.
BMC CANCER (2017)
Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy
Gerald Goh et al.
ONCOTARGET (2016)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas
Stephen Q. Wong et al.
CANCER RESEARCH (2015)
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
Michael R. Migden et al.
LANCET ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Trends in Basal Cell Carcinoma Incidence and Identification of High-Risk Subgroups, 1998-2012
Maryam M. Asgari et al.
JAMA DERMATOLOGY (2015)
Platinum and anthracycline therapy for advanced cutaneous squamous cell carcinoma
Kenta Nakamura et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma
Aleksandar Sekulic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pharmacokinetics of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Locally Advanced or Metastatic Solid Tumors: the Role of Alpha-1-Acid Glycoprotein Binding
Richard A. Graham et al.
CLINICAL CANCER RESEARCH (2011)
Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors
Patricia M. LoRusso et al.
CLINICAL CANCER RESEARCH (2011)
Radiation Monotherapy as Regional Treatment for Lymph Node-Positive Merkel Cell Carcinoma
L. Christine Fang et al.
CANCER (2010)
The Role of the Hedgehog Signaling Pathway in the Development of Basal Cell Carcinoma and Opportunities for Treatment
Ivor Caro et al.
CLINICAL CANCER RESEARCH (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Clonal integration of a polyomavirus in human Merkel cell carcinoma
Huichen Feng et al.
SCIENCE (2008)